• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Safety of combining biologics in severe asthma: Asthma-related and unrelated combinations.

作者信息

Lommatzsch Marek, Suhling Hendrik, Korn Stephanie, Bergmann Karl-Christian, Schreiber Jens, Bahmer Thomas, Rabe Klaus F, Buhl Roland, Virchow Johann Christian, Milger Katrin

机构信息

Department of Pneumology and Critical Care Medicine, University of Rostock, Rostock, Germany.

Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany.

出版信息

Allergy. 2022 Sep;77(9):2839-2843. doi: 10.1111/all.15379. Epub 2022 Jun 4.

DOI:10.1111/all.15379
PMID:35585763
Abstract
摘要

相似文献

1
Safety of combining biologics in severe asthma: Asthma-related and unrelated combinations.重度哮喘中生物制剂联合使用的安全性：与哮喘相关及不相关的联合用药
Allergy. 2022 Sep;77(9):2839-2843. doi: 10.1111/all.15379. Epub 2022 Jun 4.
2
Selection of Biologics in Severe Asthma: A Multifaceted Algorithm.重度哮喘生物制剂的选择：一种多方面的算法
J Investig Allergol Clin Immunol. 2019;29(4):325-328. doi: 10.18176/jiaci.0398. Epub 2019 Apr 10.
3
Severe T2-high asthma in the biologics era: European experts' opinion.生物制剂时代的重度 T2 高哮喘：欧洲专家意见。
Eur Respir Rev. 2019 Jul 8;28(152). doi: 10.1183/16000617.0054-2019. Print 2019 Jun 30.
4
Biologics for Asthma and Risk of Infection: Cause for Concern?哮喘生物制剂与感染风险：是否值得关注？
Immunol Allergy Clin North Am. 2019 Aug;39(3):429-445. doi: 10.1016/j.iac.2019.03.010.
5
Safety of biologicals in severe asthma patients having COVID-19.患有新冠肺炎的重度哮喘患者使用生物制剂的安全性。
Pediatr Pulmonol. 2023 Jul;58(7):2140-2141. doi: 10.1002/ppul.26450. Epub 2023 May 10.
6
Incidence of adverse events prompting switching between biologics among adults with asthma: A retrospective cohort study.成人哮喘患者中促使生物制剂转换的不良事件发生率：一项回顾性队列研究。
Allergy. 2023 Apr;78(4):1116-1119. doi: 10.1111/all.15564. Epub 2022 Nov 5.
7
A drug safety review of treating eosinophilic asthma with monoclonal antibodies.治疗嗜酸性粒细胞性哮喘的单克隆抗体药物安全性评价。
Expert Opin Drug Saf. 2019 Dec;18(12):1161-1170. doi: 10.1080/14740338.2019.1675634. Epub 2019 Oct 21.
8
Biologics in severe asthma: Outcomes in clinical trials-Similarities and differences.生物制剂在重症哮喘中的应用：临床试验结果——相似性与差异。
Expert Opin Biol Ther. 2022 Jul;22(7):855-870. doi: 10.1080/14712598.2022.2091409. Epub 2022 Jun 23.
9
Emerging Biologics in Severe Asthma.重度哮喘中的新兴生物制剂
Immunol Allergy Clin North Am. 2016 Aug;36(3):609-23. doi: 10.1016/j.iac.2016.04.001.
10
[New guidelines and new therapy options in severe asthma].[重度哮喘的新指南与新治疗选择]
MMW Fortschr Med. 2016 May 12;158(9):18-9. doi: 10.1007/s15006-016-8177-1.

引用本文的文献

1
Combining Dual Biologics Therapy for Severe Asthma: A Series of Ten Cases.联合双生物制剂治疗重度哮喘：十例系列病例
J Asthma Allergy. 2025 Apr 5;18:507-517. doi: 10.2147/JAA.S507008. eCollection 2025.
2
Roads to remission: evolving treatment concepts in type 2 inflammatory diseases.缓解之路：2型炎症性疾病不断发展的治疗理念
EClinicalMedicine. 2025 Jan 8;80:103050. doi: 10.1016/j.eclinm.2024.103050. eCollection 2025 Feb.
3
Simultaneous treatment with benralizumab and ustekinumab in a patient with severe asthma and ulcerative colitis.
在一名重度哮喘和溃疡性结肠炎患者中同时使用贝那利珠单抗和乌司奴单抗进行治疗。
Lung India. 2025 Jan 1;42(1):49-52. doi: 10.4103/lungindia.lungindia_337_24. Epub 2024 Dec 24.
4
Target Therapy in Chronic Arthritis: The Unmet Needs, State-of-the-Art on Dual Biologic Treatments, and Future Perspectives.慢性关节炎的靶向治疗：未满足的需求、双生物制剂治疗的最新进展及未来展望。
J Clin Med. 2024 Dec 1;13(23):7303. doi: 10.3390/jcm13237303.
5
Case Report: Dual monoclonal antibody therapy in chronic rhinosinusitis with nasal polyps and severe eosinophilic asthma-a proteome analysis.病例报告：双单克隆抗体疗法治疗伴有鼻息肉的慢性鼻-鼻窦炎和重度嗜酸性粒细胞性哮喘——蛋白质组分析
Front Allergy. 2024 Nov 1;5:1484931. doi: 10.3389/falgy.2024.1484931. eCollection 2024.
6
Therapeutic monoclonal antibodies in allergy: Targeting IgE, cytokine, and alarmin pathways.过敏治疗中的治疗性单克隆抗体：靶向IgE、细胞因子和警报素途径。
Immunol Rev. 2024 Nov;328(1):387-411. doi: 10.1111/imr.13380. Epub 2024 Aug 19.
7
Successful combination therapy of mepolizumab and dupilumab in a patient with EGPA: a future therapeutic option?美泊利单抗和度普利尤单抗联合治疗嗜酸性肉芽肿性多血管炎患者成功：一种未来的治疗选择？
Rheumatol Adv Pract. 2024 Aug 6;8(3):rkae093. doi: 10.1093/rap/rkae093. eCollection 2024.
8
Benralizumab Reduces Respiratory Exacerbations and Oral Glucocorticosteroid Dose in Patients with Severe Asthma and Eosinophilic Granulomatosis with Polyangiitis.贝那利珠单抗可减少重度哮喘合并嗜酸性肉芽肿性多血管炎患者的呼吸道急性加重次数并降低口服糖皮质激素剂量。
J Asthma Allergy. 2024 Jun 6;17:557-572. doi: 10.2147/JAA.S461800. eCollection 2024.
9
Monitoring mepolizumab treatment in chronic rhinosinusitis with nasal polyps (CRSwNP): Discontinue, change, continue therapy?监测美泊利单抗治疗鼻息肉型慢性鼻-鼻窦炎（CRSwNP）：停药、换药还是继续治疗？
Allergol Select. 2024 Mar 21;8:26-39. doi: 10.5414/ALX02460E. eCollection 2024.
10
Dual biologics for severe asthma and atopic dermatitis: Synopsis of two cases and literature review.用于重度哮喘和特应性皮炎的双特异性生物制剂：两例病例概述及文献综述
Respirol Case Rep. 2023 Dec 6;12(1):e01266. doi: 10.1002/rcr2.1266. eCollection 2024 Jan.